NCT05996393View on ClinicalTrials.gov

CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly

PHASE4CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

September 15, 2023

Primary Completion Date

February 20, 2025

Study Completion Date

February 27, 2025

Conditions
Aplastic Anemia
Interventions
DRUG

Ciclosporin

3-5 mg/kg/d orally, trough concentrations: 100-200 ng/ml

DRUG

Avatrombopag

60 mg/d orally, 24 weeks

DRUG

Anti-Human Thymocyte Immunoglobulin, Rabbit

rabbit anti-human thymocyte immunoglobulin (r-ATG 3mg/kg/d), intravenously, 5 days;

Trial Locations (1)

Unknown

Peking union medical college hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT05996393 - CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly | Biotech Hunter | Biotech Hunter